NorthWest Biotherapeutics Inc (NWBO)

[iclight]

Numbers are way off. 3K GBM patients per year in UK and Canada combined.

Knowing the highly selected screening of the P3 trial, a doctor would only prescribe DCVax if a patient had similar criteria to those in the trial who showed efficacy which is only 13% of the already screened 30% of all GBM patients.

To make numbers easy, 1/3 of the 3000K patients would make the screening. Of that 1000, 13% would match postive criteria of the patient population in the trial.

So 130 patients X 180,000.

So there's 23.4 million.

DCVax-D is irrelevant because it showed no ORR and is 20 years from going anywhere if they ever dust it off though there's every indication it will go the way of DCVax Prostate.

non-GBM irrelevant because they aren't close to running a P3.

But hey, just make up $1 trillion and everyone will high five!